Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.45 |
| ▸ | LMNA | P02545 | 7/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26260329 | 0.84 | MAPT (0.48) | HSD17B10MAPTGAAALDH1A1LMNA | |
| SCHEMBL26618162 | 0.84 | ALDH1A1 (0.47) | MAPTGAAALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL10348148 | 0.78 | PKM (0.49) | HSD17B10MAPTGAAALDH1A1SMN1; SMN2 | |
| SCHEMBL20265510 | 0.76 | ALDH1A1 (0.44) | MAPTGAAALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL6446115 | 0.75 | HSD17B10 (0.49) | HSD17B10MAPTGAAALDH1A1LMNA | |
| SCHEMBL20265180 | 0.75 | GABRA2 (0.54) | MAPTALDH1A1LMNASMN1; SMN2KMT2A | |
| SCHEMBL17292927 | 0.74 | HSD17B10 (0.55) | HSD17B10MAPTGAAALDH1A1LMNA | |
| SCHEMBL10347988 | 0.74 | PHOSPHO1 (0.43) | MAPTGAAALDH1A1KMT2AMEN1 | |
| SCHEMBL11901316 | 0.74 | MAPT (0.51) | MAPTALDH1A1LMNAKMT2AMEN1 | |
| SCHEMBL19814412 | 0.72 | NOTUM (0.53) | HSD17B10MAPTGAAALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3283464-B1 | FACTOR XIA INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-23 | — | — | EP | disclosed |
| US-10081617-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-09-25 | — | — | US | disclosed |
| US-20180079743-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180079743-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-03-22 | — | — | US | disclosed |
| EP-3283464-A1 | FACTOR XIa INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2018-02-21 | — | — | EP | disclosed |
| WO-2016168098-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168098-A1 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079743-A1 | FACTOR XIa INHIBITORS | F11, F2, TFPI | HSD17B10 1444/4885MAPT 3748/4885GAA 2668/4885 |
| US-10081617-B2 | Factor XIa inhibitors | F11, F2, TFPI | HSD17B10 1444/4885MAPT 3748/4885GAA 2668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.